1-Year Relative Conditional Survival by Time Period.

<p>1-Year Relative Conditional Survival by Time Period.</p

DSS Stratified by Time Period.

<p>DSS Stratified by Time Period.</p

Stepwise inclusion and exclusion of patients with urothelial carcinoma included in the SEER database from 1990–2010.

<p>Stepwise inclusion and exclusion of patients with urothelial carcinoma included in the SEER database from 1990–2010.</p

1 year relative conditional survival by time period.

<p>1 year relative conditional survival by time period.</p

Proportion of patients defined as cisplatin-ineligible (i.e., creatinine clearance >60) based on the CKD-EPI equation, Cockroft-Gault equation, and MDRD equation (n = 126).

<p>Proportion of patients defined as cisplatin-ineligible (i.e., creatinine clearance >60) based on the CKD-EPI equation, Cockroft-Gault equation, and MDRD equation (n = 126).</p

Surgical outcomes and pathologic findings of patients with MIBC who received radical cystectomy.

<p>Subgroups are based on (1) receipt or non-receipt of neoadjuvant cisplatin-based chemotherapy and (2) CrCl (above or below 60) based on the Cockroft-Gault (CG) equation.</p

Proportion of patients defined as cisplatin-eligible (i.e., creatinine clearance >60) based on the CKD-EPI equation, Cockroft-Gault equation, and MDRD equation in subsets based on age (a), race (b) and comorbidity (c).

<p>Proportion of patients defined as cisplatin-eligible (i.e., creatinine clearance >60) based on the CKD-EPI equation, Cockroft-Gault equation, and MDRD equation in subsets based on age (a), race (b) and comorbidity (c).</p

Demographic and clinicopathologic characteristics, as well as selected clinical outcomes, of patients with MIBC who received radical cystectomy.

<p>Subgroups are based on (1) receipt or non-receipt of neoadjuvant cisplatin-based chemotherapy and (2) CrCl (above or below 60) based on the Cockroft-Gault (CG) equation.</p